Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation by Calkins, H. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/182933
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 376;17 nejm.org April 27, 2017 1627
From Johns Hopkins Medical Institutions, 
Baltimore (H.C.); Department of Cardiology–
Electrophysiology, University Heart Center 
Hamburg, Hamburg (S.W.), Department of 
Cardiology, J.W. Goethe University, Frank-
furt (S.H.H.), and Boehringer Ingelheim 
Pharma, Ingelheim am Rhein (M.N.) — all 
in Germany; Section of Cardiac Electrophys-
iology, University of California, San Francisco, 
San Francisco (E.P.G.); University of Toronto, 
Toronto (A.V.); Barts Heart Centre, Saint Bar-
tholomew’s Hospital, London (R.S.), and 
Biometrics and Data Sciences Department, 
Boehringer Ingelheim, Bracknell (K.G.) — 
both in the United Kingdom; Division of Car-
diology, Saiseikai Kumamoto Hospital Car-
diovascular Center, Kumamoto, Japan (K.O.); 
St. Louis Heart and Vascular, St. Louis (H.S.); 
Department of Clinical Operations, Boeh-
ringer Ingelheim Regional Center Vienna, 
Vienna (B.B.); Department of Cardiology, 
Radboud University Medical Center, Nijme-
gen, the Netherlands (M.A.B.); and Cardiol-
ogy Department, Miulli Hospital, Acquaviva 
delle Fonti, Italy (M.G.). Address reprint re-
quests to Dr. Calkins at Johns Hopkins Med-
ical Institutions, Sheikh Zayed Tower 7125R, 
1800 Orleans St., Baltimore, MD, or at 
 hcalkins@ jhmi . edu.
* A complete list of investigators in the 
RE-CIRCUIT (Randomized Evaluation 
of Dabigatran Etexilate Compared to 
Warfarin in Pulmonary Vein Ablation: 
Assessment of an Uninterrupted Peri-
procedural Anticoagulation Strategy) 
trial is provided in the Supplementary 
Appendix, available at NEJM.org.
This article was published on March 19, 2017, 
at NEJM.org.
N Engl J Med 2017;376:1627-36.
DOI: 10.1056/NEJMoa1701005
Copyright © 2017 Massachusetts Medical Society.
BACKGROUND
Catheter ablation of atrial fibrillation is typically performed with uninterrupted 
anticoagulation with warfarin or interrupted non–vitamin K antagonist oral anti-
coagulant therapy. Uninterrupted anticoagulation with a non–vitamin K antago-
nist oral anticoagulant, such as dabigatran, may be safer; however, controlled data 
are lacking. We investigated the safety of uninterrupted dabigatran versus warfarin 
in patients undergoing ablation of atrial fibrillation.
METHODS
In this randomized, open-label, multicenter, controlled trial with blinded adjudi-
cated end-point assessments, we randomly assigned patients scheduled for catheter 
ablation of paroxysmal or persistent atrial fibrillation to receive either dabigatran 
(150 mg twice daily) or warfarin (target international normalized ratio, 2.0 to 3.0). 
Ablation was performed after 4 to 8 weeks of uninterrupted anticoagulation, 
which was continued during and for 8 weeks after ablation. The primary end point 
was the incidence of major bleeding events during and up to 8 weeks after abla-
tion; secondary end points included thromboembolic and other bleeding events.
RESULTS
The trial enrolled 704 patients across 104 sites; 635 patients underwent ablation. 
Baseline characteristics were balanced between treatment groups. The incidence 
of major bleeding events during and up to 8 weeks after ablation was lower with 
dabigatran than with warfarin (5 patients [1.6%] vs. 22 patients [6.9%]; absolute 
risk difference, −5.3 percentage points; 95% confidence interval, −8.4 to −2.2; 
P<0.001). Dabigatran was associated with fewer periprocedural pericardial tam-
ponades and groin hematomas than warfarin. The two treatment groups had a 
similar incidence of minor bleeding events. One thromboembolic event occurred 
in the warfarin group.
CONCLUSIONS
In patients undergoing ablation for atrial fibrillation, anticoagulation with uninter-
rupted dabigatran was associated with fewer bleeding complications than uninter-
rupted warfarin. (Funded by Boehringer Ingelheim; RE-CIRCUIT ClinicalTrials.gov 
number, NCT02348723.)
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Catheter ablation of atrial fibril-lation is a well-established treatment for symptomatic atrial fibrillation. Guidelines 
have incorporated catheter ablation of symptom-
atic atrial fibrillation as a class 1 or 2 indication, 
depending on previous antiarrhythmic treatment 
and type of atrial fibrillation.1-3 The most impor-
tant complications associated with ablation of 
atrial fibrillation are periprocedural stroke or 
transient ischemic attack (TIA) and cardiac tam-
ponade.3
Systemic anticoagulation before, during, and 
after ablation is important in reducing the risk 
of periprocedural cerebrovascular events.3 To mini-
mize these risks, heparin should be administered 
during ablation to maintain an activated clotting 
time of more than 300 seconds. However, there 
is less consensus on preprocedural and postpro-
cedural anticoagulation management.3 Uninter-
rupted vitamin K antagonism during the time of 
ablation of atrial fibrillation is associated with a 
lower risk of periprocedural bleeding and stroke 
than stopping vitamin K antagonism and bridg-
ing with low-molecular-weight heparin.4,5
Preliminary safety data are available from ob-
servational studies of cohorts of patients under-
going catheter ablation with uninterrupted non–
vitamin K antagonist oral anticoagulant therapy6-17; 
these data are supported by recent meta-analyses 
comparing periprocedural non–vitamin K antago-
nist oral anticoagulant therapy with uninterrupt-
ed vitamin K antagonists.18,19 The limited sys-
tematic, prospective clinical data for non–vitamin 
K antagonist oral anticoagulants in the context 
of catheter ablation of atrial fibrillation poses a 
management challenge.3,4,6-20 One exploratory con-
trolled trial involving 248 patients showed that 
the uninterrupted use of a factor Xa inhibitor 
was feasible; the incidences of thromboembolic 
events and major bleeding events were low and 
were similar to those with uninterrupted dose-
adjusted vitamin K antagonist therapy.21
Dabigatran etexilate (dabigatran) has efficacy 
and safety outcomes similar or superior to those 
of warfarin for stroke prevention in patients with 
atrial fibrillation.22,23 The favorable safety and ef-
ficacy profile of dabigatran has been consistently 
confirmed by practice-based evidence from mul-
tiple sources, including two Food and Drug Ad-
ministration studies and several independent sci-
entific groups.24-27 The RE-CIRCUIT (Randomized 
Evaluation of Dabigatran Etexilate Compared to 
Warfarin in Pulmonary Vein Ablation: Assessment 
of an Uninterrupted Periprocedural Anticoagula-
tion Strategy) trial was a prospective, random-
ized trial investigating the safety and efficacy of 
a periprocedural anticoagulation regimen with 
uninterrupted dabigatran as compared with un-
interrupted warfarin in patients undergoing ab-
lation of atrial fibrillation.
Me thods
Trial Design
The RE-CIRCUIT trial was a randomized, open-
label, multicenter, controlled trial with blinded 
adjudicated end-point assessments involving pa-
tients with nonvalvular atrial fibrillation under-
going ablation of atrial fibrillation. The trial was 
conducted in accordance with the provisions of 
the Declaration of Helsinki and the International 
Conference on Harmonisation Good Clinical Prac-
tice guidelines.28,29 The protocol (available with 
the full text of this article at NEJM.org) was ap-
proved by the institutional review board or inde-
pendent ethics committee at each participating 
center. Written informed consent was obtained 
from all the patients before trial entry. The trial 
was conducted under the guidance of a steering 
committee, and data (both adjudicated and non-
adjudicated) were scrutinized by an independent 
data and safety monitoring committee. All pri-
mary and secondary end points were adjudicated 
by an independent committee whose members 
were unaware of the trial-group assignments. 
The trial was designed by the authors in collabo-
ration with the sponsor (Boehringer Ingelheim). 
The authors vouch for the accuracy and com-
pleteness of the data and analyses and for the 
fidelity of the trial to the protocol. The develop-
ment of the manuscript was led by the first au-
thor, in collaboration with all the authors. All the 
authors made the decision to submit the manu-
script for publication. Assistance with manuscript 
preparation was provided by a medical writer 
funded by the sponsor.
Trial Population
Full inclusion and exclusion criteria are listed in 
the protocol. Patients 18 years of age or older were 
included in the trial if they had paroxysmal or 
persistent nonvalvular atrial fibrillation with 
planned ablation of atrial fibrillation, had docu-
mented atrial fibrillation within 24 months be-
A Quick Take 
is available at 
NEJM.org
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fore screening, and were eligible for treatment 
with dabigatran (150 mg twice daily) according 
to the local prescribing information. Key exclusion 
criteria were permanent atrial fibrillation, atrial 
fibrillation secondary to an obvious reversible 
cause, and valvular atrial fibrillation.
Treatment
Patients were randomly assigned in blocks (1:1 ra-
tio) to receive either dabigatran (150 mg twice 
daily) or warfarin (combination of 1, 3, and 5 mg, 
with dose adjustment for a target international 
normalized ratio [INR] of 2.0 to 3.0), with no 
stratification. The Rosendaal method was used 
to evaluate the percentage of time that a patient’s 
INR was in the therapeutic range.30 Patients who 
had previously taken a vitamin K antagonist and 
were assigned to the warfarin group started the 
trial medication when the INR was less than 3.0 
(<2.6 in patients at Japanese sites ≥70 years of 
age); dabigatran treatment was initiated when a 
patient’s INR was less than 2.0.
The trial consisted of four sequential periods: 
a screening period of 0 to 2 weeks; a preablation 
treatment period of 4 to 8 weeks, to achieve the 
desired stable anticoagulation range in patients 
receiving warfarin; a postablation treatment pe-
riod of 8 weeks (starting with the ablation pro-
cedure); and a follow-up period of 1 week (Fig. S1 
in the Supplementary Appendix, available at NEJM 
.org). All the patients were to undergo preablation 
transesophageal echocardiography to rule out left 
atrial thrombi. The morning dose of dabigatran 
was taken on the day of the ablation at the pa-
tient’s usual scheduled time. Ablation was per-
formed with uninterrupted anticoagulation treat-
ment, and anticoagulation was continued for 
8 weeks after the procedure. Unfractionated hepa-
rin was administered after the placement of femo-
ral sheaths before or immediately after transseptal 
puncture. During the ablation procedure, achiev-
ing and maintaining an activated clotting time 
of more than 300 seconds was recommended. 
Dabigatran administration was continued in the 
evening of the procedure at the scheduled time, 
with a minimum delay of 3 hours after sheath 
removal and achievement of hemostasis.
The procedure for ablation of atrial fibrillation 
was performed according to the recommendations 
and guidelines of a 2012 expert consensus state-
ment.3 Patients underwent ablation at the discre-
tion of the attending electrophysiologist; the proce-
dure included pulmonary-vein isolation and any 
additional substrate-modification approach typi-
cally performed in that laboratory. Radiofrequen-
cy energy was typically used; however, other en-
ergy sources such as cryoablation or laser ablation 
were allowed.
All the patients were to have a follow-up visit 
1 week after the treatment with trial medication 
ended, which was 8 weeks after the ablation pro-
cedure. Any decision to continue anticoagulation 
with nontrial medication after the follow-up pe-
riod was based on the recommendations and 
guidelines1,3 and at the treating physician’s dis-
cretion.
Trial End Points
Primary End Point
The primary end point was the incidence of ad-
judicated major bleeding events as defined by the 
International Society on Thrombosis and Hemo-
stasis (ISTH).31 Major bleeding events were con-
sidered from the start of the ablation procedure, 
from the first femoral puncture to up to 8 weeks 
after ablation. Prespecified subgroups were ana-
lyzed with the use of descriptive statistics (explor-
atory testing). Information on major bleeding 
events requiring medical attention (e.g., compres-
sion of a puncture site, the use of vitamin K or 
prothrombin complex concentrates, or a proce-
dure or surgical intervention) was also collected.
Secondary End Points
The secondary efficacy and safety end points were 
the incidence of the following events during and 
up to 8 weeks after ablation: a composite of stroke, 
systemic embolism, or TIA; minor bleeding events; 
and a composite of major bleeding events and 
thromboembolic events (stroke, systemic embo-
lism, or TIA). Minor bleeding events were defined 
as clinical bleeding events that did not fulfill ISTH 
criteria for major bleeding events.
Adverse Events
All adverse events throughout the trial period were 
recorded and analyzed. An adverse event was 
defined as any untoward medical occurrence in 
a patient administered a trial treatment. A severe 
adverse event was defined as an event that was 
incapacitating or caused an inability to work or 
perform usual activities. Data on adverse events 
were collected from the time of signing of the in-
formed consent, and events were further classified 
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as serious or nonserious during the course of the 
trial. Efficacy and safety end points were reported 
only as adverse events. Because efficacy and safety 
end points could also be serious adverse events, 
these events were not reported as serious adverse 
events on the serious-adverse-event form to the 
sponsor and consequently were not reported in an 
expedited manner to the competent authorities.
Statistical Analysis
The trial had a planned enrollment of at least 
290 patients per treatment group undergoing ab-
lation across 114 international sites. Calculations 
were performed with the use of nQuery Advisor, 
version 7.0 (Statistical Solutions). The trial was 
exploratory because the sample required to pro-
vide sufficient power to establish formal nonin-
feriority with an acceptable upper limit of the 95% 
confidence interval (e.g., 1.5) would have made the 
trial unfeasible (>2000 patients per group). On the 
basis of multiple scenarios, it was decided that a 
minimum of 290 patients who could be evaluated 
per treatment group would be enough to provide 
clinically meaningful information. Under the as-
sumption of no difference in absolute rates of 
major bleeding events between the two treatment 
groups, the chosen total sample of 580 would pro-
duce a confidence interval for the difference be-
tween dabigatran and warfarin with an upper 
limit of 2.48%, if the absolute rate of major 
bleeding events were 0.59%. If the absolute rate 
of major bleeding events were 4.55%, the upper 
limit of the confidence interval of the difference 
would have been 4.98%.32 To minimize any poten-
tial bias, a central randomization strategy using 
computer-generated sequences was implemented 
through an interactive computerized response 
system.
To provide a statistical framework to identify 
differences between the treatment groups, nom-
inal P values were determined. The primary and 
secondary end point analyses were based on the 
ablation set. The ablation set included all ran-
domly assigned patients who had taken at least 
one dose of trial drug and who had undergone 
the ablation procedure. Point estimates for the 
incidence of major bleeding events and their two-
sided 95% confidence intervals, based on the nor-
mal approximation of independent binomial dis-
tribution without stratification, were determined. 
The risk difference between dabigatran and war-
farin was calculated, and the two-sided 95% con-
fidence interval and corresponding P value were 
estimated. In general, adverse events were ana-
lyzed descriptively. The treated set (all randomly 
assigned patients who had taken ≥1 dose of trial 
drug) were included in the safety analysis, and the 
summaries were based on the actual treatment 
received. Statistical analysis and reporting of ad-
verse events concentrated on events that emerged 
during treatment.
R esult s
Trial Participants
The trial enrolled 704 patients across 104 sites in 
11 countries from April 2015 through July 2016, 
of whom 678 patients underwent randomization. 
The ablation set included 635 patients (317 in the 
dabigatran group and 318 in the warfarin group) 
(Fig. 1). Demographic and clinical characteris-
tics were well balanced between the treatment 
groups at baseline (Table 1). Dabigatran adher-
ence was calculated on the basis of the number 
of capsules taken; nonadherence was recorded 
when adherence was not between 80% and 120% 
of the expected dose. Warfarin adherence was 
monitored with the use of the INR. The mean ad-
herence with dabigatran was 97.6%, and patients 
receiving INR-adjusted warfarin were within the 
guideline-defined target INR range (2.0 to 3.0) 
for 66% of the time overall. The majority of pa-
tients (86.1% in the dabigatran group and 84.3% 
in the warfarin group) received trial medication 
for at least 8 weeks after ablation, and more than 
98% received trial medication for at least 6 weeks, 
with no meaningful difference between the treat-
ment groups (Table S1 in the Supplementary Ap-
pendix).
Primary End Point
There were 27 patients overall with adjudicated 
major bleeding events during and up to 8 weeks 
after ablation. The percentage of patients with 
major bleeding events was significantly lower in 
the dabigatran group than in the warfarin group 
(5 patients [1.6%] vs. 22 patients [6.9%]; abso-
lute risk difference, –5.3 percentage points; 95% 
confidence interval [CI], –8.4 to –2.2; P<0.001). 
The relative risk reduction versus warfarin was 
77.2%. The robustness of the primary end point 
was supported by a Cox proportional-hazards 
analysis showing a hazard ratio of 0.22 for dabi-
gatran versus warfarin (95% CI, 0.08 to 0.59) 
The New England Journal of Medicine 
Downloaded from nejm.org at Radboud University Nijmegen on March 14, 2019. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
n engl j med 376;17 nejm.org April 27, 2017 1631
Uninterrupted Dabigatr an vs. Warfarin
(Fig. 2). The numbers of major bleeding events 
in the two groups were as follows: pericardial 
tamponade, 1 event in the dabigatran group and 
6 events in the warfarin group; pericardial effu-
sion, 1 and 0; groin bleeding, 2 and 2; groin he-
matoma, 0 and 8; intracranial bleeding, 0 and 2; 
pseudoaneurysm, 0 and 1; gastrointestinal bleed-
ing, 1 and 2; and hematoma, 0 and 2 (Table S2 in 
the Supplementary Appendix). In particular, dabi-
gatran was associated with fewer major bleeding 
events than warfarin from the time of ablation to 
7 days after ablation (4 vs. 17 major bleeding 
events) (Table S3 in the Supplementary Appendix).
In the dabigatran group, 131 patients (41.3%) 
received the final dose of dabigatran less than 
4 hours before the transseptal puncture, 116 pa-
tients (36.6%) 4 to less than 8 hours before the 
puncture, and 62 patients (19.6%) 8 hours or more 
before the puncture. The information was lacking 
for 8 patients. Two major bleeding events occurred 
in the “within 4 hours” group and 3 major bleed-
ing events in the “within 4 to 8 hours” group. In 
the warfarin group, the mean INR at the time of 
the ablation was similar in patients with major 
bleeding events and those without such events 
(2.4 and 2.3, respectively). The mean intraproce-
dural activated clotting time in patients with major 
bleeding events was 374 seconds in the dabigatran 
group and 314 seconds in the warfarin group; in 
patients without major bleeding events, the time 
was 329 seconds in the dabigatran group and 
344 seconds in the warfarin group.
Figure 1. Enrollment, Randomization, and Follow-up.
678 Underwent randomization
704 Patients were enrolled
26 Were excluded
339 Were assigned to receive
150 mg of dabigatran twice daily
339 Were assigned to receive warfarin
338 Received ≥1 dose of 
dabigatran (treated set)
338 Received ≥1 dose of
warfarin (treated set)
317 Underwent ablation (ablation set) 318 Underwent ablation (ablation set)
21 Discontinued treatment prematurely
10 Had adverse events
4 Declined to continue medication
2 Did not adhere to the protocol
5 Had other reasons
20 Discontinued treatment prematurely
3 Had adverse events
7 Declined to continue medication
1 Did not adhere to the protocol
9 Had other reasons
8 Discontinued treatment prematurely
4 Had adverse events
3 Declined to continue medication
1 Had other reasons
7 Discontinued treatment prematurely
2 Had adverse events
4 Declined to continue medication
1 Had other reasons
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Characteristic
Dabigatran, 
150 mg Twice Daily 
(N = 317)
Warfarin 
(N = 318)
Age — yr 59.1±10.4 59.3±10.3
Male sex — no. (%) 230 (72.6) 245 (77.0)
Mean body-mass index† 28.5 28.8
Mean CHA2DS2-VASc score‡ 2.0 2.2
Activated clotting time
No. of patients analyzed 312 308
Mean — sec 330 342
Medical history — no. (%)
Congestive heart failure 31 (9.8) 34 (10.7)
Left ventricular dysfunction 25 (7.9) 23 (7.2)
Coronary artery disease 32 (10.1) 48 (15.1)
Percutaneous coronary intervention 16 (5.0) 19 (6.0)
Previous myocardial infarction 10 (3.2) 15 (4.7)
Hypertension 166 (52.4) 177 (55.7)
Previous stroke 10 (3.2) 9 (2.8)
Previous major bleeding or predisposition 3 (0.9) 4 (1.3)
Previous GI bleeding or gastritis 24 (7.6) 21 (6.6)
Renal disease 7 (2.2) 14 (4.4)
Diabetes mellitus 30 (9.5) 34 (10.7)
Atrial fibrillation — no. (%)
Paroxysmal 213 (67.2) 219 (68.9)
Persistent 86 (27.1) 81 (25.5)
Long-standing persistent 18 (5.7) 18 (5.7)
Medication use — no. (%)§
Vitamin K antagonists 95 (28.1) 86 (25.4)
Dabigatran 45 (13.3) 36 (10.7)
Rivaroxaban 29 (8.6) 29 (8.6)
Apixaban 21 (6.2) 30 (8.9)
Edoxaban 3 (0.9) 0
NSAIDs 66 (19.5) 78 (23.1)
Proton-pump inhibitors 73 (21.6) 79 (23.4)
Statins 106 (31.4) 101 (29.9)
Beta-blockers 195 (57.7) 204 (60.4)
*  Plus–minus values are means ±SD. The ablation set included all randomly assigned patients who had taken at least 
one dose of trial drug and who had undergone the ablation procedure. GI denotes gastrointestinal, and NSAID non-
steroidal antiinflammatory drug.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  The CHA2DS2-VASc score reflects the risk of stroke among patients with atrial fibrillation. Scores range from 0 to 9, 
with higher scores indicating greater risk.
§  Values are for the treated set (338 patients in each group).
Table 1. Baseline Demographic and Clinical Characteristics (Ablation Set).*
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Subgroup analyses of the incidence of adju-
dicated major bleeding events during and up to 
8 weeks after ablation were generally consistent 
with the overall results favoring the dabigatran 
group. Major bleeding events were, in general, less 
frequent in the dabigatran group irrespective of 
sex, age, creatinine clearance, CHA2DS2-VASc score 
(which reflects the risk of stroke among patients 
with atrial fibrillation), status with respect to previ-
ous hypertension, type of ablation, geographic re-
gion, and body-mass index (Fig. S2 in the Supple-
mentary Appendix).
In the dabigatran group, 4 patients with a major 
bleeding event required medical action; only the 
pericardial tamponade required procedural in-
tervention (namely, pericardial drainage). Idaru-
cizumab, a specific dabigatran-reversal agent, 
was not used to treat any of the patients in the 
dabigatran group who required medical atten-
tion. In the warfarin group, 21 patients with a 
major bleeding event required medical attention, 
and 11 of these patients required an intervention 
(6 underwent pericardial drainage, 3 underwent 
surgical repair of the femoral artery, 1 underwent 
polyp removal, and 1 received a retroperitoneal 
intervention) (Table S3 in the Supplementary Ap-
pendix).
Secondary End Points
There were no events of stroke, systemic embo-
lism, or TIA in the dabigatran group and only one 
event (TIA) in the warfarin group from the time 
of ablation until 8 weeks after ablation. The in-
cidence of minor bleeding events was similar in 
the two treatment groups (59 patients [18.6%] 
in the dabigatran group and 54 patients [17.0%] in 
the warfarin group). The composite incidence of 
major bleeding events and thromboembolic events 
(stroke, systemic embolism, or TIA) was lower in 
the dabigatran group than in the warfarin group 
(5 patients [1.6%] vs. 23 patients [7.2%]).
Adverse Events
Serious adverse events were reported in 18.6% of 
the patients in the dabigatran group and 22.2% 
of the patients in the warfarin group (Table S4 
in the Supplementary Appendix). No fatal events 
were reported in either treatment group. In addi-
tion, dabigatran was associated with fewer severe 
adverse events (3.3% with dabigatran and 6.2% 
with warfarin). The incidence of adverse events 
leading to discontinuation of trial treatment was 
low in both groups (5.6% with dabigatran and 
2.4% with warfarin) (Table 2). In 15 patients, the 
ablation procedure was canceled or postponed 
for a variety of investigator-identified reasons; a 
thrombus identified on transesophageal echo-
cardiography was reported in 1 patient (Table S5 
in the Supplementary Appendix).
Discussion
This multicenter, randomized, controlled trial 
assessed the safety and efficacy of uninterrupted 
dabigatran as compared with warfarin as a peri-
procedural anticoagulant in patients undergoing 
ablation of atrial fibrillation. Dabigatran was as-
sociated with a significantly lower rate of major 
bleeding events than INR-adjusted warfarin, and 
there were no differences in the incidence of 
stroke or systemic embolism.
One of the most feared complications of abla-
tion of atrial fibrillation is stroke. Previous clini-
cal trials have shown that continuous vitamin K 
antagonism is associated with fewer embolic 
events than interrupted treatment.3,4 However, 
data on the use of non–vitamin K antagonist oral 
anticoagulants around the time of catheter abla-
tion are limited.15-17,21 Most electrophysiologists 
have interrupted the dose of non–vitamin K an-
Figure 2. Kaplan–Meier Plot of Time to First Adjudicated Major Bleeding 
Event (Ablation Set).
Major bleeding events were defined according to the International Society 
on Thrombosis and Hemostasis.31 The hazard ratio was calculated with a 
Cox proportional-hazards model, with a Wald confidence interval. The in-
set shows the same data on an expanded y axis.
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tagonist oral anticoagulants before catheter ab-
lation, out of concern that bleeding complications 
could lead to worse outcomes in the presence of 
an “irreversible” anticoagulant. High-risk patients 
receiving non–vitamin K antagonist oral antico-
agulants often had their treatment changed over 
to vitamin K antagonists periprocedurally, so that 
ablation could be performed with continuous 
anticoagulation, and then were switched back to 
a non–vitamin K antagonist oral anticoagulant 
1 to 2 months after ablation. This is because 
higher-risk patients, such as older patients with 
persistent atrial fibrillation, would have had a 
period of time before ablation and after sheath 
removal during which there was no anticoagu-
lant present, which could increase the risk of an 
embolic event. However, the practice of switching 
anticoagulants is cumbersome for patients and 
physicians, and the growing use of non–vitamin K 
antagonist oral anticoagulants has made this ap-
proach impractical.
Cohort data suggest that interrupted and con-
tinuous non–vitamin K antagonist oral antico-
agulants have similar safety and effectiveness in 
the context of ablation of atrial fibrillation.33 In-
terpretation of the available data is limited by 
small samples, small numbers of events, and 
nonrandomized or retrospective study designs.15-17 
A recent meta-analysis including 7996 patients 
from 19 observational studies showed that non–
vitamin K antagonist oral anticoagulants did not 
differ significantly from interrupted or continu-
ous warfarin treatment with respect to the preven-
tion of thromboembolic events but may be associ-
ated with a lower risk of overall bleeding and 
minor bleeding complications.18 The only pro-
spective, randomized clinical trial performed to 
date was the VENTURE-AF trial.21 This con-
trolled trial involving 248 patients undergoing 
ablation of atrial fibrillation showed that the 
uninterrupted use of a factor Xa inhibitor is fea-
sible, with no meaningful difference in throm-
boembolic events or major bleeding events as 
compared with uninterrupted vitamin K antago-
nists. The major limitation of this trial was the 
small sample and low numbers of major bleed-
ing events and thromboembolic events.
The major concern of performing catheter ab-
lation with uninterrupted non–vitamin K antago-
nist oral anticoagulant therapy is the risk of bleed-
ing, particularly life-threatening bleeding such as 
pericardial tamponade. In the present trial, the 
Event
Dabigatran, 
150 mg Twice Daily  
(N = 338)
Warfarin 
(N = 338)
Total 
(N = 676)
number (percent)
Any adverse event 225 (66.6) 242 (71.6) 467 (69.1)
Severe adverse event† 11 (3.3) 21 (6.2) 32 (4.7)
Adverse event leading to treatment discontinuation 19 (5.6) 8 (2.4) 27 (4.0)
Serious adverse event 63 (18.6) 75 (22.2) 138 (20.4)
Fatal adverse event 0 0 0
Immediately life-threatening event 1 (0.3) 2 (0.6) 3 (0.4)
Event that resulted in clinically significant or  
persistent disability or incapacity
0 1 (0.3) 1 (0.1)
Event that required hospitalization 26 (7.7) 34 (10.1) 60 (8.9)
Event that prolonged hospitalization 13 (3.8) 22 (6.5) 35 (5.2)
Other‡ 29 (8.6) 27 (8.0) 56 (8.3)
*  The treated set included all randomly assigned patients who had taken at least one dose of trial drug. A patient may be counted as having 
an event that fulfills more than one seriousness criterion. Percentages were calculated with the total number of patients per treatment as 
the denominator.
†  A severe adverse event was defined as an event that is incapacitating or causes an inability to work or perform usual activities.
‡  The “other” category included events deemed to be serious by the investigator in that they were important medical events that, after appro-
priate medical judgment, may have required medical or surgical intervention to prevent any of the outcomes mentioned previously.
Table 2. Adverse Events during the Treatment Period (Treated Set).*
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rate of major bleeding events was significantly 
lower in the dabigatran group than in the warfa-
rin group. In particular, the rates of pericardial 
bleeding and groin hematoma were lower with 
dabigatran. The mechanism of reducing major 
bleeding events with dabigatran may be related 
to the more specific mechanism of action (direct 
thrombin inhibition rather than a decrease in the 
production of several coagulation factors) and 
shorter half-life of dabigatran as compared with 
warfarin, as well as the presence of normal levels 
of factor VII and a stable anticoagulation effect. 
Another potential advantage of the periprocedural 
use of dabigatran is the availability of idaruci-
zumab, a dabigatran-specific reversal agent that 
can achieve an immediate and complete rever-
sal of the anticoagulant effect.1 However, even 
though this agent became available during the 
RE-CIRCUIT trial, all the bleeding events in the 
dabigatran group were managed without the need 
for dabigatran reversal, which is reassuring. These 
outcomes are consistent with the results of the 
Randomized Evaluation of Long-Term Anticoagu-
lant Therapy (RE-LY) trial,23 showing superiority of 
dabigatran (150 mg twice daily) versus a vita-
min K antagonist, and of several robust and in-
dependent real-world studies that support the 
findings of the RE-LY trial.34,35
A potential limitation of our trial was the 
open-label design. The different dosing schedule 
of dabigatran, need for blood testing, and adjust-
ments in the dose of warfarin made blinding 
clinically impractical. However, all outcome events 
were independently adjudicated by a blinded events 
committee. The sample size that would have been 
required for a formal noninferiority trial was pro-
hibitive. However, the results observed, and the 
fact that dabigatran was ultimately superior to 
warfarin with respect to the primary end point, 
made our observations clinically relevant. We 
found that periprocedural anticoagulation with 
uninterrupted dabigatran (150 mg twice daily) 
was associated with fewer bleeding events than 
uninterrupted vitamin K antagonism.
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